Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:33:37 EDT Sat 05 Oct 2024
Enter Symbol
or Name
USA
CA



Q:VSTM - VERASTEM INC - https://www.verastem.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VSTM - Q0.22.81·3.165.02.87+0.103.6459.01,1631,9432.85  2.92  2.80514.22  2.1019:33:07Sep 1015 min RT 2¢

Recent Trades - Last 10 of 1943
Time ETExPriceChangeVolume
19:33:07Q2.99990.22998,000
18:29:05Q2.810.0410
18:24:42Q2.930.16250
17:48:20Q2.810.0410
17:45:18Q2.820.0510
17:10:12Q2.820.053
16:38:36Q2.810.048
16:21:27Q2.930.16100
16:16:04Q2.940.175
16:01:56Q2.870.10342

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-10 16:05U:VSTMNews ReleaseVerastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
2024-09-10 07:30U:VSTMNews ReleaseVerastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
2024-09-03 07:30U:VSTMNews ReleaseVerastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
2024-08-08 16:05U:VSTMNews ReleaseVerastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
2024-07-29 16:01U:VSTMNews ReleaseVerastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
2024-07-23 23:20U:VSTMNews ReleaseVerastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
2024-07-23 16:05U:VSTMNews ReleaseVerastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
2024-07-12 07:30U:VSTMNews ReleaseVerastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
2024-07-08 07:30U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-01 07:30U:VSTMNews ReleaseVerastem Oncology Announces Addition to Russell 3000(TM) and Russell Microcap(TM) Indexes
2024-05-24 07:00U:VSTMNews ReleaseVerastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
2024-05-23 17:01U:VSTMNews ReleaseVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
2024-05-09 16:02U:VSTMNews ReleaseVerastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
2024-05-07 07:30U:VSTMNews ReleaseVerastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
2024-04-18 16:05U:VSTMNews ReleaseVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
2024-04-04 07:30U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 07:00U:VSTMNews ReleaseGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
2024-03-14 16:05U:VSTMNews ReleaseVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
2024-03-11 07:30U:VSTMNews ReleaseVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
2024-03-05 17:27U:VSTMNews ReleaseVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer